3-Hydroxyphenylisocyanat | 23159-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-Hydroxyphenylisocyanat
• 英文别名: m-Isocyanatophenol；3-Isocyanatophenol
• CAS: 23159-70-8
• 化学式: C₇H₅NO₂
• 分子量: 135.122
• InChiKey: BVOIFIHUIVLWMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  80 °C(Press: 0.05 Torr)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Hydroxyphenylisocyanat 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(3-hydroxyphenyl)urea
  参考文献：
  名称：

  Discovery of N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

  摘要：

  In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a structure-based design, that 3-aminoindazole could serve as an efficient hinge-binding template for kinase inhibitors. By incorporating an N,N'-diaryl urea moiety at the C4-position of 3-aminodazole, a series of RTK inhibitors were generated, which potently inhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor families. A number of compounds with potent oral activity were identified by utilizing an estradiol-induced mouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model. In particular, compound 17p (ABT-869) was found to possess favorable pharmacokinetic profiles across different species and display significant tumor growth inhibition in multiple preclinical animal models.

  DOI：

  10.1021/jm061280h
• 作为产物：
  描述：

  间羟基苯甲酸 在 二苯基膦叠氮化物 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 3-Hydroxyphenylisocyanat
  参考文献：
  名称：

  Synthesis and structure-activity relationship study of pyrrolidine-oxadiazoles as anthelmintics against Haemonchus contortus

  摘要：

  Parasitic roundworms (nematodes) are significant pathogens of humans and animals and cause substantive socioeconomic losses due to the diseases that they cause. The control of nematodes in livestock animals relies heavily on the use of anthelmintic drugs. However, their extensive use has led to a widespread problem of drug resistance in these worms. Thus, the discovery and development of novel chemical entities for the treatment of parasitic worms of humans and animals is needed. Herein, we describe our medicinal chemistry optimization efforts of a phenotypic hit against Haemonchus contortus based on a pyrrolidine-oxadiazole scaffold. This led to the identification of compounds with potent inhibitory activities (IC50 = 0.78-22.4 mu M) on the motility and development of parasitic stages of H. contortus, and which were found to be highly selective in a mammalian cell counter-screen. These compounds could be used as suitable chemical tools for drug target identification or as lead compounds for further optimization. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112100

文献信息

• Synthesis and SAR of New 5-Phenyl-3-ureido-1,5-benzodiazepines as Cholecystokinin-B Receptor Antagonists
  作者：Antonella Ursini、Anna M. Capelli、Robin A. E. Carr、Paolo Cassarà、Mauro Corsi、Ornella Curcuruto、Giovanni Curotto、Michele Dal Cin、Silvia Davalli、Daniele Donati、Aldo Feriani、Harry Finch、Gabriella Finizia、Giovanni Gaviraghi、Marc Marien、Giorgio Pentassuglia、Stefano Polinelli、Emiliangelo Ratti、Aldo Reggiani、Giorgio Tarzia、Giovanna Tedesco、Maria E. Tranquillini、David G. Trist、Frank T. M. Van Amsterdam

  DOI：10.1021/jm990967h

  日期：2000.10.1

  A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective CCK-B affinity. Addition of substituents at the urea side chain provided in some cases more potent compounds. Moreover the introduction of bulky substituents

  合成了一系列5-苯基-3-脲基苯并二氮杂-2，4-二酮，并作为胆囊收缩素-B（CCK-B）受体拮抗剂进行了评估。结构活性关系（SAR）研究表明，N-1取代基对于有效和选择性CCK-B亲和力的重要性。在某些情况下，在脲侧链上添加取代基可提供更有效的化合物。此外，在N-1处引入笨重的取代基（如金刚烷基甲基）和拆分外消旋脲导致了我们的铅化合物GV150013。
• Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN)
  作者：Chunhua Ma、Kang Jin、Jiangying Cao、Lei Zhang、Xiaoguang Li、Wenfang Xu

  DOI：10.1016/j.bmc.2013.01.068

  日期：2013.4

  Aminopeptidase N (APN/CD13) over expressed on tumor cells, plays a critical role in tumor invasion, metastasis, and tumor angiogenesis. Here we described the design, synthesis and preliminary activity studies of novel leucine ureido derivatives as aminopeptidase N (APN/CD13) inhibitors. The results showed that compound 8c had the most potent inhibitory activity against APN with the IC50 value to 0

  氨肽酶N（APN / CD13）在肿瘤细胞上过度表达，在肿瘤侵袭，转移和肿瘤血管生成中起关键作用。在这里，我们描述了新型亮氨酸脲基衍生物作为氨肽酶N（APN / CD13）抑制剂的设计，合成和初步活性研究。结果表明，化合物8c对APN的抑制作用最强，IC 50值为0.06±0.041μM，可用于进一步的抗癌药研究。
• Development of 1,4-benzodiazepine cholecystokinin type B antagonists
  作者：Mark G. Bock、Robert M. DiPardo、Ben E. Evans、Kenneth E. Rittle、Willie L. Whitter、Victor M. Garsky、Kevin F. Gilbert、James L. Leighton、Kenneth L. Carson

  DOI：10.1021/jm00078a018

  日期：1993.12

  4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK), are described. Derived by reasoned modification of the CCK-A selective 3-carboxamido-1,4-benzodiazepine, MK-329, this paper chronicles the development of potent, orally effective compounds in which selectivity for the CCK-B receptor subtype was achieved. The principal lead structure that emerged from these studied is

  描述了一系列3-（芳基脲基）-5-苯基-1,4-苯并二氮杂卓，肽激素胆囊收缩素（CCK）的非肽拮抗剂。通过对CCK-A选择性3-甲酰胺基-1,4-苯并二氮杂卓MK-329的合理修饰而衍生，本文记载了有效的，口服有效的化合物的开发，其中对CCK-B受体亚型具有选择性。从这些研究中得出的主要铅结构是L-365,260，该化合物已提交临床评估。讨论了通过适当的结构修饰来调节这些苯并二氮杂the的受体相互作用的能力的细节，这暗示了进一步完善这类化合物的CCK-B受体亲和力和选择性的可能性。
• [EN] DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE DIAMINOCYCLOHEXANE ET LEURS UTILISATIONS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013012829A1

  公开（公告）日：2013-01-24

  The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.

  本发明提供了Formula (I)的化合物或其立体异构体，或其药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是NPY Y4受体的激动剂、部分激动剂和调节剂，可用于治疗和预防各种疾病和症状。
• [EN] TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS<br/>[FR] ANTAGONISTES DE TRPM8 ET LEUR UTILISATION DANS LE CADRE THÉRAPEUTIQUE
  申请人：AMGEN INC

  公开号：WO2012177896A1

  公开（公告）日：2012-12-27

  Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have the above structure, where the definitions of the variables are provided herein.

  式（I）的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和症状方面具有用处，并可用于制备用于治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括但不限于偏头痛和神经病性疼痛。式（I）的化合物具有上述结构，其中变量的定义在此提供。